RR1

7.14%

1.3¢ reach resources limited

Your post has done the same

First 32 Last

Share
Profile

Follow
roblun

5,276 Posts.

2129

20/10/23

15:00

Post #: 70451767
Share

Originally posted by Maverick7: ↑

WARNING: the following will trigger some holders

1. Li results were originally scheduled for early Oct, then mid-Oct, now early Nov. Looks very suspicious, especially considering it wouldn't be a good look at the conference if they released poor results this week and the share price had taken a big fall. Anyone with experience knows that good news is usually reported immediately, whereas bad news usually is delayed as long as possible, yes it's technically illegal, but most junior resource companies operate this way. Also, they would likely already be in receipt of a large portion (if not all) of their results as labs usually dispatch results in batches on a FIFO basis.

2. Mentioning that they're going to get any expert geochemist to analyse the results and ratios is also not a good sign as probably means the Li results were not good, so they're going to try pad the results to soften the blow with ratios to try give hope that they might find something better later.

3. He didn't look and sound very confident when he mentioned the upcoming results.

4. The market cap is relatively high for their stage of exploration, so if results are poor expect a large fall possibly to 0.5/0.6c as other Li cos have been hammered after releasing poor results.

I may be wrong, just my 2 cents as a paid down-ramper.

PS: @Yevgeny ask EFE holders if they think @TheArchitect was a bonus
PPS: @roblun constantly pasting copious pages from announcements unnecessarily clogs the forum and provides minimal value, please summarise instead, thanks.

Expand

Your post has done the same

Last edited by roblun: 20/10/23

RR1 Price at posting: 1.2¢ Sentiment: Buy Disclosure: Held
19 Upvote

1 Great analysis

Reply

Top Stories

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

There are more pages in this discussion • 17 more messages in this thread...

First 32 Last

Add RR1 (ASX) to my watchlist

(20min delay)
Last 1.3¢		Change -0.001(7.14%)		Mkt cap ! $11.36M

Open	High	Low	Value	Volume
1.5¢	1.5¢	1.3¢	$13.66K	1.010M

Buyers (Bids)

No.	Vol.	Price($)
7	621973	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	150991	1

View Market Depth

No.	Vol.	Price($)
7	621973	0.013
5	877916	0.012
5	813724	0.011
10	1144995	0.010
6	1242399	0.009

Price($)	Vol.	No.
0.015	150991	1
0.016	830345	4
0.017	574431	4
0.018	2295274	3
0.019	1455148	5

Last trade - 16.10pm 11/07/2024 (20 minute delay)

RR1 (ASX) Chart

Your post has done the same

Canadian fieldwork yields multiple pegmatites for Trinex

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Your post has done the same

Top Stories

Canadian fieldwork yields multiple pegmatites for Trinex

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News